Pfizer reshuffles exec team to emphasize oncology

In anticipation of regulatory clearance for its proposed $43 billion acquisition of Seagen (Nasdaq: SGEN), US pharma giant Pfizer (NYSE: PFE) today announced a reorganization of its R&D team to create a leading company in the battle against cancer.

As a result, effective today, Dr Chris Boshoff, will join Pfizer’s executive leadership team as chief oncology R&D and executive vice president reporting to chairman and chief executive Albert Bourla. Under his leadership, Pfizer will continue to invest in its fight against cancer and Dr Boshoff will be the single point of accountability for the entire oncology pipeline – from discovery to early and late-phase clinical development.

“We are delighted to welcome Chris Boshoff to our executive leadership team as he works to accelerate the delivery of the next generation of cancer breakthroughs to patients around the world,” said Dr Bourla, adding: “About 1 in 3 people will be diagnosed with cancer during their lifetime in the United States, which means just about every family will be impacted by this dreaded disease. Chris is an exceptional physician-scientist with the vision and expertise to unleash the scale and strength of Pfizer’s ambition in cancer research.”